• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Twist Bioscience (TWST)'s Lilly TuneLab Deal Means For Shareholders

    Simply Wall St·09/29/2026 15:14:31
    Listen to the news
    • Twist Bioscience previously announced an agreement with Lilly TuneLab, Eli Lilly's AI and machine learning drug discovery platform, to supply antibody characterization data services that link Twist's wet lab protocols with TuneLab prediction models for faster molecule down selection.
    • The arrangement embeds Twist Bioscience's antibody workflows into TuneLab's federated training system, which can deepen pharma relationships while generating recurring, data-rich service demand tied directly to AI-driven discovery pipelines.
    • We will now examine how Twist Bioscience's investment narrative could shift as its antibody protocols become embedded within Lilly's TuneLab platform.

    Scan beyond Twist Bioscience and this Lilly TuneLab tie-up to size up other AI drug discovery players in our curated list of 37 healthcare AI stocks.

    Twist Bioscience Investment Narrative Recap

    To own Twist Bioscience, you need to believe that demand for synthetic DNA, NGS tools and antibody services can scale fast enough to narrow losses and support its push toward breakeven. The Lilly TuneLab agreement fits that view by tying Twist protocols directly into AI driven discovery, but it does not remove the near term pressure from ongoing adjusted EBITDA losses and cash burn.

    The biggest near term swing factor remains whether management can keep gross margins above 50% while holding operating costs in check. Incremental service volume through TuneLab only matters if it comes with disciplined spending. The main risk is that continued unprofitability and customer concentration in NGS could force Twist to raise capital again, which could dilute you as a shareholder.

    The Lilly TuneLab agreement is the key announcement here because it directly ties Twist Bioscience antibody workflows to a large pharma backed AI platform. That connection can support the existing catalyst of broader customer adoption, since TuneLab users can order Twist services using preferred protocols and pricing that are already integrated with their prediction models.

    For you, the operational question is execution. Twist still needs to convert this embedded access into steady, high quality service demand that supports revenue growth forecasts around 17.1% a year while working toward its adjusted EBITDA breakeven goal. If volumes underwhelm or pricing comes under pressure as competition in NGS and SynBio intensifies, the agreement could have limited impact on the core profitability challenge.

    Twist Bioscience's current analyst narrative points to revenues of $753.3 million and earnings of $127.9 million by 2029, based on 20.4% yearly revenue growth and an earnings swing of about $264.6 million from a loss of $136.7 million today.

    Uncover why Twist Bioscience's fair value indicates a 41% potential downside to its current price, suggesting that the current premium may not be sustainable.

    NasdaqGS:TWST 1-Year Stock Price Chart
    NasdaqGS:TWST 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the lowest Twist Bioscience analysts worry more about commoditization risk than customer growth. They were only penciling in revenue of about $668.6 million and earnings of $118.5 million by 2029, well below consensus. Those forecasts came before the Lilly TuneLab agreement, so you may see these narratives shift.

    Explore 3 other Twist Bioscience fair value estimates, including one that suggests there could be as much as 41% downside from the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking for more Twist Bioscience sized investment ideas?

    Once you have formed a view on Twist Bioscience, it can help to cross check that thesis against other opportunities using the Simply Wall St Screener. That way you are comparing this stock with a wider set of businesses that share the qualities you care about most.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.